Mr. D'Orazio has spent the last twenty-plus years in business development, sales, marketing and strategic planning. He has co-founded two pharmaceutical companies and recently led an IPO exit. He has also worked for notable companies Merck and Pfizer as well as startups.
Mr. Fraker has worked for more than 40 years as a wildlife biologist in Canada and the USA. He spent much of the first half of his career researching the ecology and behavior of Arctic marine mammals, particularly bowhead and beluga whales. Since 1998, he has focused on applications of fertility control to manage the growth of populations of large mammals. Mr. Fraker conducted the first trials of SpayVac contraceptive pZP vaccine on a terrestrial wildlife species, fallow deer, later extending this work to white-tailed and black-tailed deer, wild horses, and African elephants. Following the first trial—no treated fallow deer became pregnant over three years—he became convinced that SpayVac, as a long-lasting, single-dose contraceptive vaccine, has great potential for addressing significant wildlife management issues. His research on wild horses and African elephants has been in collaboration with Dr. Bechert.
VP, Research and Development
Dr. Bechert worked as a veterinarian in private practice and at a free-ranging wildlife park for several years prior to earning her PhD in reproductive endocrinology. She has been conducting research for the past 20 years with interests in the reproductive physiology of endangered species, development of novel diagnostic and population management tools, as well as nutritional and pharmacokinetic studies with wildlife. Dr. Bechert and Mr. Fraker have collaborated on research to explore the effects of SpayVac in wild horses and African elephants. Dr. Bechert also works in academia developing new professional graduate programs in science. LinkedIn Profile
Vaccine Manufacturing and Methods
With 18 years of experience in developing novel vaccines for cancer and infectious diseases, Marc is one of the early developers of Spayvac and later oversaw the implementation of Spayvac in the field with multiple collaborators. Over his career he held various positions of increasing responsibility including Chief Science Officer, Chief Operating Officer and Chief Executive Officer of a publicly traded vaccine development company. His expertise is in immunology, immune therapies and vaccine development from design to preclinical testing, applying regulatory requirements and phase 1-2 clinical trials. He has in the past and currently is a technical and strategic consultant for immunotherapy and vaccine companies.
Director of Immunology
An immunologist, Dr. Kroeger brings expertise in vaccinology and antibody technology to SpayVac. Prior to joining Spayvac as a consulting immunologist, Dr. Kroeger directed a lab that generated monoclonal antibodies for research. David earned his Ph.D. in immunology from the University of Saskatchewan in 2012, where he focused on mechanisms of immune activation. Following this training, he received postdoctoral training in cancer immunotherapy at BC Cancer Agency.